Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breast Cancer Study Primary Endpoint Should Be Time To Progression - Cmte.

Executive Summary

Time to progression should replace response rate as the primary endpoint in clinical trials for first-line hormonal drugs that treat metastatic breast cancer, FDA's Oncologic Drugs Advisory Committee said Sept. 10.

You may also be interested in...



Letrozole Should Not Replace Tamoxifen As Standard Comparator, Cmte. Says

FDA should not replace AstraZeneca's Nolvadex (tamoxifen) with Novartis' Femara (letrozole) as the standard comparator for first-line hormonal drugs for the treatment of metastatic breast cancer, FDA's Oncologic Advisory Drugs Committee agreed Sept. 10.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel